Type specificity and significance of different isotypes of serum antibodies to human papillomavirus capsids

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 456-462

  Wang, Z H ^a,c   Kjellberg, L ^c   Abdalla, H ^a   Wiklund, F ^c   Eklund, C ^a   Knekt, P ^d   Lehtinen, M ^d,e   Kallings, I ^b   Lenner, P ^c   Hallmans, G ^c   Mahlck C G ^c   Wadell, G ^c   Schiller, J ^f   Dillner, Joakim ^a,c,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN; VIRUS DNA;

ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROEPIDEMIOLOGY; SEXUAL BEHAVIOR; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CAPSID; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN ISOTYPES; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEROEPIDEMIOLOGIC STUDIES; SEXUAL BEHAVIOR; TUMOR VIRUS INFECTIONS;

EID: 0034101777     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315232     Document Type: Article

References (31)

1. Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiological evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993; 85:958-64.
2. Dillner J, Kallings I, Brihmer C, et al. Seropositivity to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996; 173:1394-8.
3. Wideroff L, Schiffman MH, Nonnenmacher B, et al. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 1995; 172:1425-1430
4. Chua K, Wiklund F, Lenner P, et al. A prospective cohort study on the risk to develop cervical intraepithelial neoplasia among healthy subjects with serum antibodies to HPV, in comparison with presence of HPV DNA in cervical smears. Int J Cancer 1996;68:54-9.
5. de Gruijl TD, Bontkes HJ, Walboomers JMM, et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective non-intervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 1997; 89:630-8.
6. Wang ZH, Konya J, Åvall-Lundkvist E, Sapp M, Dillner J, Dillner L. Human papillomavirus antibody responses among patients with incident cervical carcinoma. J Med Virol 1997; 52:436-40.
7. Lehtinen M, Dillner J, Knekt P, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma. BMJ 1996; 312:537-9.
8. Shah KV, Viscidi RP, Alberg AJ, Helzlsouer KJ, Comstock GW. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 1997; 6:233-7.
9. Brinton LA, Hamman RF, Huggins GR, et al. Sexual and reproductive risk factors for invasive squamous cell cervical cancer. J Natl Cancer Inst 1987; 79:23-30.
10. af Geijersstam V, Kibur M, Wang ZH, et al. Stability over time of human papillomavirus type 16 antibody levels. J Infect Dis 1998; 177:1710-4.
11. Wideroff L, Schiffman MH, Hoover R, et al. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV16 DNA-positive and negative women. J Infect Dis 1996; 174:937-43.
12. Wang ZH, Christensen ND, Schiller JT, Dillner J. A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 1997; 78:2209-15.
13. Spiegelbery L, Beck L, Kocher P, Fanslow W, Lucas A. Role of interleukin-4 in human immunoglobulin E formation in hu-PBL-SCID mice. J Clin Invest 1994; 93:711-7.
14. Kawano Y, Noma T, Yata J. Regulation of human IgG subclass production by cytokines. J Immunol 1994; 153:4948-58.
15. Inoue R, Kondo N, Kobayashi Y, Fukutomi O, Ori T. IgG2 deficiency associated with defects in production of interferon-gamma: comparison with common variable immunodeficiency. Scand J Immunol 1995; 41:130-4.
16. Briere F, Servet-Delprat C, Bridon JM, Saint-Remy JM, Banchereau J. Human interleukin 10 induces naive surface immunoglobulin D′ (sIgD′) B cells to secrete IgG1 and IgG3. J Exp Med 1994; 179:757-62.
17. Snapper CM, Mond J. Towards a comprehensive view of immunoglobulin class switching. Immunol Today 1993; 14:15-7.
18. Wikström A, Van Doornum GJJ, Quint WGV, Schiller JT, Dillner J. Identification of human papillomavirus seroconversions. J Gen Virol 1995; 76: 529-39.
19. Saikku P, Leinonen M, Tenkanen L, et al. Chronic Chlamydiae pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992; 116:273-8.
20. Kjellberg L, Wiklund F, Ångström T, Wadell G, Dillner J, Mählck CG. A population-based study of human papillomavirus deoxyribonucleic acid testing for predicting cervical intraepithelial neoplasia. Am J Obslet Gynecol 1998; 179:1497-502.
21. Evander M, Edlund K, Boden E, et al. Comparison of a one-step and a two-step polymerase chain reaction with degenerate general primers in a population-based study of human papillomavirus infection in young Swedish women. J Clin Microbiol 1992; 30:987-92.
22. Evander M, Wadell G. A general primer for amplification and detection of genital human papillomavirus types. J Virol Methods 1991; 31:239-50.
23. Dillner J, Lenner P, Lehtinen M, et al. A population-based seroepidemiological study of cervical cancer. Cancer Res 1994; 54:134-41.
24. Dillner J, Wiklund F, Lenner P, et al. Antibodies against linear and conformational epitopes of human papillomavirus type 16 that independently associate with cervical cancer. Int J Cancer 1995; 60:377-82.
25. Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997; 89:245-50.
26. Stellato G, Nieminen P, Aho M, Lehtinen T, Lehtinen M, Paavonen J. Type 1 cytokine response and treatment outcome of genital lesions. Genitourin Med 1997; 73:387-90.
27. Matsumoto K, Yoshikawa H, Yasugi T, et al. Balance of IgG subclasses toward human papillomavirus type 16 (HPV16) L1-capsids is a possible predictor for the regression of HPV16-positive cervical intraepithelial neoplasia. Biochem Biophys Res Commun 1999; 258:128-31.
28. Bontkes HJ, de Gruijl TD, Walboomers JMM, et al. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J Gen Virol 1999; 80:409-17.
29. af Geijersstam V, Wang ZH, Lewensohn-Fuchs I, Schiller JT, Forsgren M, Dillner J. Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969-1989. Int J Cancer 1998; 76:341-4.
30. Kjellberg L, Wang ZH, Wiklund F, et al. Sexual behavior and papillomavirus exposure in cervical intraepithelial neoplasia: a population-based case-control study. J Gen Virol 1999; 80:391-8.
31. Dillner J. Serology of human papillomavirus. Cancer J 1995; 8:264-9.